GNNSF - FDA OKs first SARS-CoV-2 neutralizing antibody test

The FDA authorizes the emergency use of Genscript Biotech's ([[GNNSF]]) cPass SARS-CoV-2 Neutralizing Antibody Detection Kit for the identification of neutralizing antibodies to the coronavirus from recent or prior infection.This is the first assay approved in the U.S. that detects SARS-CoV-2 neutralizing antibodies (their effect on infection is still being researched). The agency has OK'd more than 50 blood tests that detect binding antibodies which attach to the coronavirus but may not decrease the infection and destruction of cells.

For further details see:

FDA OKs first SARS-CoV-2 neutralizing antibody test